Back to Journals » Drug Design, Development and Therapy » Volume 9

Targeting the hypoxia pathway to treat pancreatic cancer

Authors Erickson L, Highsmith Jr. E, Fei P, Zhang J

Received 14 January 2015

Accepted for publication 10 March 2015

Published 8 April 2015 Volume 2015:9 Pages 2029—2031

DOI https://doi.org/10.2147/DDDT.S80888

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Prof. Dr. Wei Duan


Lori A Erickson,1 W Edward Highsmith Jr,1 Peiwen Fei,2 Jun Zhang1

1Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA; 2University of Hawaii Cancer Center, University of Hawaii, Honolulu, HI, USA

Abstract: The correlation between hypoxia and pancreatic cancer has long been discussed. Hao’s research team made many efforts on revealing the oncogenic function of hypoxic inducible factor-1 (HIF-1) in pancreatic cancer progression and development in recent years. Based on their research, they linked micro-environmental regulation of pancreatic cancer and its clinical significance. Hao’s research team suggests it is a promising approach to target HIF-1 for the management of pancreatic cancer progression and invasion.

Keywords: hypoxia, HIF-1, pancreatic cancer

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]